Struggling to read this morning?
The REX Offer was limited to an aggregate value of £6.8 million and received total applications in excess of this amount. Avacta has determined only to allocate REX Offer Shares to existing Avacta retail shareholders and therefore a total of approximately £5.4 million
Let's not forget they have already licensed out pre|CISION to point (lilly)
So they certainly aren't adverse to the idea.
He's always said the lead asset ava6k he would like to keep in house though. With this new money he should be able to do that now.
We have carried the risk of clinical trials at absolutely no benefit to ourselves. Intact a negative impact.
But how were we to know after 7 cohorts and no MTD, a platform that works that the share price would be 50p
In hindsight we would have all waited until now (if you believe in the tech). Hindsight is a wonderful thing.